Rezolute Inc (RZLT NASDAQ) stock market data APIs
$5.2407
0.04(0.8%)
as of July 10, 2025
Try our APIs with
free plan!
Rezolute Inc Financial Data Overview
Price chart is built with
Anychart
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company's lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Prev. Close
5.2407
Open
5.2761
High
5.4013
Low
5.091
52 wk Range
2.215-6.1856
Market Cap
456 M
Shares Outstanding
86 815 K
EPS
-0.27
Beta
1.04
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Rezolute Inc data using free add-ons & libraries
Get Rezolute Inc Fundamental Data
Rezolute Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -77 116 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Rezolute Inc News
New
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused...
Rezolute ticks higher following disclosure of CFO stock buy
[Shares] Bluberries/iStock via Getty Images * Rezolute is up ~5% in Tuesday afternoon trading following the disclosure of a significant purchase of shares from its CFO. * Daron Evans on Tuesday b...
Rezolute CFO Evans buys $20,250 in company stock
Rezolute , Inc. (NASDAQ:RZLT) Chief Financial Officer Daron Evans has recently purchased 5,000 shares of the company’s common stock at $4.05 per share, according to a Form 4 filing with the Securiti...
Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Rezolute, Inc. (NASDAQ:RZLT) was one of the stocks that was covered in that article. Wall Street analysts believe R...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
